» Articles » PMID: 38989827

ACSL4 Upregulates IFI44 and IFI44L Expression and Promotes the Proliferation and Invasiveness of Head and Neck Squamous Cell Carcinoma Cells

Overview
Journal Cancer Sci
Specialty Oncology
Date 2024 Jul 11
PMID 38989827
Authors
Affiliations
Soon will be listed here.
Abstract

Reprogramming of cellular energy metabolism, including deregulated lipid metabolism, is a hallmark of head and neck squamous cell carcinoma (HNSCC). However, the underlying molecular mechanisms remain unclear. Long-chain acyl-CoA synthetase 4 (ACSL4), which catalyzes fatty acids to form fatty acyl-CoAs, is critical for synthesizing phospholipids or triglycerides. Despite the differing roles of ACSL4 in cancers, our data showed that ACSL4 was highly expressed in HNSCC tissues, positively correlating with poor survival rates in patients. Knockdown of ACSL4 in HNSCC cells led to reduced cell proliferation and invasiveness. RNA sequencing analyses identified interferon-induced protein 44 (IFI44) and interferon-induced protein 44-like (IFI44L), encoded by two interferon-stimulated genes, as potential effectors of ACSL4. Silencing IFI44 or IFI44L expression in HNSCC cells decreased cell proliferation and invasiveness. Manipulating ACSL4 expression or activity modulated the expression levels of JAK1, tyrosine kinase 2 (TYK2), signal transducer and activator of transcription 1 (STAT1), interferon α (IFNα), IFNβ, and interferon regulatory factor 1 (IRF1), which regulate IFI44 and IFI44L expression. Knockdown of IRF1 reduced the expression of JAK1, TYK2, IFNα, IFNβ, IFI44, or IFI44L and diminished cell proliferation and invasiveness. Our results suggest that ACSL4 upregulates interferon signaling, enhancing IFI44 and IFI44L expression and promoting HNSCC cell proliferation and invasiveness. Thus, ACSL4 could serve as a novel therapeutic target for HNSCC.

Citing Articles

IRF1 is a core transcriptional regulatory circuitry member promoting AML progression by regulating lipid metabolism.

Zhang F, Li Z, Fang F, Hu Y, He Z, Tao Y Exp Hematol Oncol. 2025; 14(1):25.

PMID: 40025540 PMC: 11871635. DOI: 10.1186/s40164-025-00612-z.


Unraveling 's biofunction in human disease.

Du J, Luo H, Ye S, Zhang H, Zheng Z, Liu K Front Oncol. 2024; 14:1436576.

PMID: 39737399 PMC: 11682996. DOI: 10.3389/fonc.2024.1436576.


ACSL4 upregulates IFI44 and IFI44L expression and promotes the proliferation and invasiveness of head and neck squamous cell carcinoma cells.

Rupa D, Chuang H, Hu C, Su W, Wu S, Lee H Cancer Sci. 2024; 115(9):3026-3040.

PMID: 38989827 PMC: 11462949. DOI: 10.1111/cas.16236.

References
1.
Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

2.
Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, Taniguchi T . Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell. 1990; 63(2):303-12. DOI: 10.1016/0092-8674(90)90163-9. View

3.
Pan H, Wang X, Huang W, Dai Y, Yang M, Liang H . Interferon-Induced Protein 44 Correlated With Immune Infiltration Serves as a Potential Prognostic Indicator in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2020; 10:557157. PMC: 7573551. DOI: 10.3389/fonc.2020.557157. View

4.
Huang W, Tung S, Chen Y, Chen P, Chu P . IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. BMC Cancer. 2018; 18(1):609. PMC: 5977745. DOI: 10.1186/s12885-018-4529-9. View

5.
Chen B, Liu J, Ho T, Ding X, Mo Y . ERK-mediated NF-κB activation through ASIC1 in response to acidosis. Oncogenesis. 2016; 5(12):e279. PMC: 5177778. DOI: 10.1038/oncsis.2016.81. View